Snail IN-1 是一种口服有效的 Snail 抑制剂(靶标 Ka 为 0.36 μM),可通过破坏 Snail-CBP 相互作用、降低乙酰化并增加多泛素化水平来加速 Snail 蛋白降解,且不改变其他 EMT 转录因子,同时能减轻动脉粥样硬化斑块负荷、调控炎症及斑块稳定性相关因子、下调 CCL5、CXCL10、MMP2 和 MMP9 并上调 α-平滑肌肌动蛋白,具有抗炎及斑块稳定活性,可用于动脉粥样硬化的研究。
产品编号: MS-P70747 纯度: 98.27% CAS No.: 3083216-69-4 分子式: C21H23N5O2S 分子量: 409.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Snail IN-1 是一种口服有效的 Snail 抑制剂(靶标 Ka 为 0.36 μM),可通过破坏 Snail-CBP 相互作用、降低乙酰化并增加多泛素化水平来加速 Snail 蛋白降解,且不改变其他 EMT 转录因子,同时能减轻动脉粥样硬化斑块负荷、调控炎症及斑块稳定性相关因子、下调 CCL5、CXCL10、MMP2 和 MMP9 并上调 α-平滑肌肌动蛋白,具有抗炎及斑块稳定活性,可用于动脉粥样硬化的研究。

生物实验数据

生物活性 Snail IN-1 is an orally effective Snail inhibitor with a target Ka of 0.36 μM that disrupts the Snail-CBP interaction to accelerate Snail protein degradation by reducing acetylation and increasing polyubiquitination levels without altering other EMT transcription factors, and it alleviates atherosclerotic plaque burden, modulates inflammation- and plaque stability-related factors, downregulates CCL5, CXCL10, MMP2, and MMP9 while upregulating α-smooth muscle actin, exhibiting anti-inflammatory and plaque-stabilizing activities and being useful for the study of atherosclerosis.
IC50 & Target

CXCR2

 

MMP-9

 

MMP-10

 

Recombinant Snail Protein

0.36 μM (Ki)

体外研究
(In Vitro)

Snail IN-1 (compound S29) (0.1-10 μM; 48 h) 可在体外以浓度依赖的方式强效下调 HUVECs 中的 Snail 蛋白水平,且不改变 Snail 的 mRNA 水平,提示其调控作用发生在转录后阶段。
Snail IN-1 (5-60 μM; 48 h) 在浓度高达 60 μM、孵育 48 h 后,对 HUVECs 无明显细胞毒性。
Snail IN-1 (5 μM; 0-240 min) 可加速 HUVECs 中 Snail 蛋白的降解,降低其稳定性。
Snail IN-1 (2.5-20 μM; 48 h) 可特异性下调 HUVEC 中的 Snail 蛋白水平,而不影响其他 EMT 转录因子 (Zeb1、Slug、Twist) 的蛋白或 mRNA 水平。
Snail IN-1 (5 μM; 24 h) 通过破坏 Snail 与 CBP 的相互作用、降低 Snail 乙酰化水平并增加人脐静脉内皮细胞 (HUVECs) 中 Snail 的多聚泛素化来促进 Snail 降解。
Snail IN-1 (2.5 μM; 24 h) 可显著下调 TNF-α 刺激的 HUVECs 中促动脉粥样硬化因子 (CCL5、CXCL10、MMP-9、MMP-2) 的 mRNA 水平。
Snail IN-1 (1.25-5 μM; 24 h) 以浓度依赖的方式抑制 TNF-α 刺激的 HUVEC 中 CCL5 和 CXCL10 蛋白的表达。
Snail IN-1 (2.5 μM; 24 h) 可通过改变经 TNF-α 刺激的 HUVEC 的分泌谱来损伤单核细胞的募集。

Western Blot Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 0.1, 1.25, 2.5, 5, 10 μM
Incubation Time: 48 h
Result: Reduced Snail protein levels (normalized to β-actin) to 0.27 relative to vehicle control at 10 μM.
Significantly reduced Snail protein levels at 0.1, 1.25, 2.5, and 5 μM.
Showed no significant changes in Snail mRNA levels across all tested concentrations.

Cell Cytotoxicity Assay

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 5, 10, 20, 40, 60 μM
Incubation Time: 48 h
Result: Showed no significant reduction in HUVEC viability, with cell viability remaining above 90% relative to vehicle control across all tested concentrations.

Western Blot Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 5 μM; with cycloheximid (CHX)
Incubation Time: 0, 30, 60, 120, 240 min
Result: Increased the degradation rate of Snail protein compared to vehicle-treated cells.
Lowered relative Snail protein levels at all time points after CHX addition, with a more pronounced decrease over time.

Western Blot Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 5 μM; 2.5, 5, 10, 20 μM
Incubation Time: 48 h
Result: Potently reduced Snail protein levels at 5 μM, but had no appreciable effect on the abundance of Zeb1, Slug, or Twist protein.
Showed no significant changes in mRNA levels of Zeb1, Slug, Twist, or Snail across tested concentrations.

Cell Migration Assay

Cell Line: TNF-α-stimulated human umbilical vein endothelial cells (HUVECs); THP-1 monocytes
Concentration: 2.5 μM
Incubation Time: 24 h
Result: Resulted in a significant reduction in THP-1 monocyte migration when using conditioned medium from Snail IN-1-treated HUVECs compared to medium from control cells.
体内研究
(In Vivo)

Snail IN-1 (25-50 mg/kg; 灌胃; 每日; 4 周) 在高脂饮食喂养的 ApoE-/- 小鼠中发挥剂量依赖性抗动脉粥样硬化作用,通过降低炎性趋化因子 (CCL5、CXCL10) 和基质降解酶 (MMP2、MMP9) 减少斑块负荷,同时增加斑块稳定因子 (胶原蛋白、α-SMA)。
Snail IN-1 (2000 mg/kg; 灌胃; 单剂量) 对 C57BL/6 小鼠具有良好的耐受性,不会造成急性器官损伤或功能紊乱。

Animal Model: ApoE-/- mice (high-fat diet-induced atherosclerotic model; treated for 4 weeks post-modeling)
Dosage: 25 mg/kg; 50 mg/kg
Administration: i.g.; daily; 4 weeks
Result: Reduced aortic plaque area to 11.33% at 25 mg/kg and a lower unspecified value at 50 mg/kg relative to control.
Reduced intraplaque CCL5 area to ~2% (from control ~15%) and CXCL10 area to ~1.5% (from control ~5%) at 50 mg/kg.
Increased collagen area in plaques to ~45% (from control ~40%) and α-SMA area to ~10% (from control ~3%) at 50 mg/kg.
Reduced intraplaque MMP2 area by 64.2% and MMP9 area by 60% relative to control at 50 mg/kg.
Animal Model: C57BL/6 mice
Dosage: 2000 mg/kg
Administration: i.g.; single dose
Result: Showed no adverse effects, changes in body weight, or organ weight abnormalities.
Exhibited normal tissue architecture with no pathological alterations in heart, liver, spleen, lung, kidney, and brain via histopathological analysis.
Demonstrated serum levels of hepatic injury markers (ALT, AST), renal function markers (BUN, Scr), and metabolic indicators (Glu, LAC) comparable to vehicle control with no statistically significant differences.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 409.50
分子式 C21H23N5O2S
CAS No. 3083216-69-4

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (244.20 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4420 mL12.2100 mL24.4200 mL61.0501 mL
5 mM0.4884 mL2.4420 mL4.8840 mL12.2100 mL
10 mM0.2442 mL1.2210 mL2.4420 mL6.1050 mL
15 mM0.1628 mL0.8140 mL1.6280 mL4.0700 mL
20 mM0.1221 mL0.6105 mL1.2210 mL3.0525 mL
25 mM0.0977 mL0.4884 mL0.9768 mL2.4420 mL
30 mM0.0814 mL0.4070 mL0.8140 mL2.0350 mL
40 mM0.0611 mL0.3053 mL0.6105 mL1.5263 mL
50 mM0.0488 mL0.2442 mL0.4884 mL1.2210 mL
60 mM0.0407 mL0.2035 mL0.4070 mL1.0175 mL
80 mM0.0305 mL0.1526 mL0.3053 mL0.7631 mL
100 mM0.0244 mL0.1221 mL0.2442 mL0.6105 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础